Patent classifications
C07D277/14
Compound as PPAR agonist and application thereof
The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.
TREATMENT OF OTITIS MEDIA
A method of treating otitis media in a subject is described that includes administering to the subject a therapeutically effective amount of an Actin-Related Protein 2/3 Complex (Arp2/3) inhibitor. The role of Arp2/3 in otitis media was identified using comprehensive proteomic and metabolomic studies of otitis media using the chinchilla model.
SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
Nitrosation Reagents and Methods
Provided are compounds that can find use as nitrosation reagents. Provided are nitrosation methods that include reacting a substrate with one of the provided nitrosation reagents and thereby generating a nitrosation product. Provided are kits including a nitrosation reagent. Provided are compositions wherein the nitrosation reagent is enriched in the .sup.15N isotope.
COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF
The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.
Reduction of the odor of monothiocarbonate compounds by addition of oxidants
A process reduces the odor of compounds with al least one five-membered cyclic monothiocarbonate group, referred to as monothiocarbonate compounds. The monothiocarbonate compounds are in are liquid phase and are brought into contact with an oxidant.
Reduction of the odor of monothiocarbonate compounds by addition of oxidants
A process reduces the odor of compounds with al least one five-membered cyclic monothiocarbonate group, referred to as monothiocarbonate compounds. The monothiocarbonate compounds are in are liquid phase and are brought into contact with an oxidant.